Status:
TERMINATED
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics an...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Females can be of childbearing or non-childbearing potential
- Subjects who have relapsing (relapsed = 6 weeks ago; this being at least a second episode) mild to moderate UC (score of 4 - 11 on the MTWI at Screening and with an endoscopy score of = 2). Diagnosis of UC originally must be established by sigmoidoscopy or colonoscopy, and have compatible histology.
- As confirmed through signed informed consent, the subject must understand and be able, willing and likely to fully comply with study procedures and restrictions
- Exclusion criteria:
- Subjects with severe UC according to the MTWI (score \>11) and subjects who have been in relapse for \> 6 weeks.
- Subjects are not eligible for this study if they have Crohn's Disease, proctitis (where the extent of inflammation = 15 cm), bleeding disorders, or active ulcer disease.
- Positive stool culture for enteric pathogens (including Salmonella, Shigella, Yersinia, Aeromonas, Plesiomonas or Campylobacter).
- Presence of Clostridium difficile toxin present or with ova or parasites as detected by microscopy.
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00457171
Start Date
December 1 2004
Last Update
May 18 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.